Drug Interaction Monitoring and Management
Monitoring for Adverse Effects
- The American Heart Association recommends monitoring for muscle pain, tenderness, or weakness, especially with fever or malaise, which could indicate statin-induced myopathy, and checking creatine kinase levels if symptoms develop 1, 2
- The American Heart Association suggests considering baseline and periodic liver function tests due to potential hepatotoxicity with statins 2
- Patients on semaglutide should be monitored for hypoglycemia, especially if doses of other medications are changed, and semaglutide dosing should be adjusted according to glycemic response and tolerability 1, 2
Risk Mitigation Strategies
- The American College of Cardiology recommends starting with appropriate rosuvastatin dosing (not exceeding 20 mg daily) due to febuxostat interaction, and considering monitoring liver enzymes and creatine kinase at baseline and periodically 2
- Patients should be educated about symptoms of myopathy that require immediate medical attention, such as muscle pain, tenderness, or weakness, especially with fever or malaise 1, 2